中化合成與Molecular Targeting Technologies (MTTI) 合作

中化生 瞄準癌症藥市場

Molecular Targeting Technologies, Inc. (MTTI) is a Pennsylvania-based biotechnology company primarily focused on the development of small molecules for the molecular imaging of diseases such as cancer, bacterial infections, neurodegenerative diseases, cardiovascular ischemia and stroke. MTTI is also advancing therapeutic human monoclonal antibody for Rabies post-exposure treatment and Fusion Protein Technology for development of a Botulinum neurotoxin vaccine. In addition, MTTI is building a research reagents business for an immediate revenue stream and currently offers a range of innovative fluorescence based products and bead based products for in vitro and in vivo research applications.

【2011/01/21 經濟日報】中化合成生技（1762）宣布，該公司為了從原料藥產業跨入蛋白質藥物市場，已與美國MITI新藥研發公司簽下合作意向書，將以具抗癌及抗菌的化合物，添加在中化合成產品中，爭取多項癌症藥品商機。中化生昨日股價上漲0.6元，以63.9元坐收。法人分析，中化生去年在器官移植用藥MMF及新增客戶挹注下，全年營收12.09億元，稅後純益1.76億元，每股稅後純益2.27元。中化生表示，該公司與MTTI公司將共同開發抗癌新藥，將由MTTI公司擁有的抗癌及抗菌標的關鍵性化合物，崁入中化合成既有原料藥Rapamycin，雙方共同發展全新藥物。中化生指出，這項新藥主要用來治療乳癌、血癌、腦癌、肺癌、肝癌等之疾病，其中抗乳癌及肺癌治療已進入一期臨床試驗階段。依據中化生與MTTI的合作方案，未來量化上市後，中化生將是該抗癌原料藥的主要生產供應商，MTTI公司將負責臨床試驗，並負責新藥上市申請，及全球市場之開發與推廣。中化生過去發展向來以化學原料藥為主，雖然也同時擁有生技發酵技術，可以朝蛋白質藥物發展。中化生現有產品中，器官移植用藥MMF及肌肉鬆弛劑MCB在北美市占率都已第一名，降膽固醇用藥PVTS則為今年成長動能最強的產品，主因競爭廠商同類產品未通過美國查廠，因此帶動中化生的PVTS將因轉單效應，出貨量呈倍數成長。

 

Molecular Targeting Technologies, Inc. (MTTI)

Product Candidate	Indication	Development Status
99mTc-glucarate products
AMISCAN	Myocardial Ischemia	Phase II
BTSCAN	Breast Cancer Imaging	Phase II
Fusion Protein Vaccine Technology
Botulinum Toxin Vaccine	Botulinum prophylaxis	Preclinical
Monoclonal Antibodies
Human Anti-Rabies Mab	Rabies post-exposure treatment	Phase l
New Imaging Products
Zn-DPA - B	Breast	Preclinical
Zn-DPA - G	Glioma	Preclinical
Zn-DPA - I	Bacterial Infections	Preclinical
Zn-DPA - H	Heart Ischemia	Preclinical
Zn-DPA - P	Prostate	Preclinical
SapC-DOPS	Tumor Imaging	Preclinical
Cu64-CNND1-B	Breast Cancer	Preclinical
Cu64-CNND1-L	Lung Cancer	Preclinical